Difference between revisions of "Collaborator:Resources"

From NAMIC Wiki
Jump to: navigation, search
 
(27 intermediate revisions by 4 users not shown)
Line 1: Line 1:
'''Collaborating with National Centers for Biomedical Computing'''
+
Back to [[NA-MIC_Collaborations|NA-MIC Collaborations]]
  
This information is for prospective applicants to the NIH Roadmap related R01s  http://grants.nih.gov/grants/guide/pa-files/PAR-07-249.html (revision of [http://grants.nih.gov/grants/guide/pa-files/PAR-05-063.html PAR-05-063]) and R21s http://grants.nih.gov/grants/guide/pa-files/PAR-07-250.html (revision of [http://grants.nih.gov/grants/guide/pa-files/PAR-06-223.html PAR-06-223]) ('''Collaborating with National Centers for Biomedical Computing'''). Please [mailto:kikinis@bwh.harvard.edu contact us] if you are interested in a collaborative project with NA-MIC.
+
*This page contains information for prospective external collaborators. NIH has established funding sources for collaborating with the NCBC's.
  
>>PAs:
+
* Click [[Collaborator:FAQ|'''here''']] for a description of the process for collaborating with NA-MIC. This should be read first.
>>
 
  
Please also read the following 2 documents:
+
*The following PAR is available for funding collaborative research with NCBCs:
 +
**http://grants.nih.gov/grants/guide/pa-files/PAR-12-001.html (R01) (active January 2012-2015)
  
* [[Collaborator:FAQ_for_funding_via_NIH_PAR-06-223|This page]] describes the process for collaborating with NA-MIC and should be read first.
+
Please [mailto:kikinis@bwh.harvard.edu contact us] if you are interested in a collaborative project with NA-MIC.
  
* [[Media:Na-mic-overview.doc|This document]] provides a 5-page summary of NA-MIC, suitable as a starting point for the 5-page summary required with your submission. We recommend that this 5-page summary be modified to include the nature of the proposed collaboration.
+
*In addition to contacting the center, you are encouraged to contact the NIH Program Officer Vinay Pai, Ph.D. (NIBIB) or the Lead Science Officer Michael Ackermann, Ph.D. (NLM) for NA-MIC.
  
In addition to contacting the center, you are encouraged to contact the NIH Program Officer Grace Peng, Ph.D. (NIBIB) or the Lead Science Officer Michael Ackermann, Ph.D. (NLM) for NA-MIC.
+
'''Please note key dates:'''  [http://grants1.nih.gov/grants/funding/submissionschedule.htm standard NIH submission dates] for R01s apply to this grant.
  
'''Please note key dates:'''
+
*Notes 2010-03:
 
+
**New [http://grants.nih.gov/grants/funding/424/index.htm forms]
Application Receipt Date(s): February 15, 2007; May 17, 2007; January 17, 2008
+
**New structure: (page 108 of the pdf version)
 
+
***1 page specific aims
Peer Review Date(s): June-July2007, October-November 2007; June-July 2008
+
***12 pages for '''Research Strategy'''
 
+
***(a) '''Significance''':  
Council Review Date(s): October 2007, January 2008, October 2008
+
****Explain the importance of the problem or critical barrier to progress in the field that the proposed project addresses.
 
+
****Explain how the proposed project will improve scientific knowledge, technical capability, and/or clinical practice in one or more broad fields.
Earliest Anticipated Start Date(s): December 1, 2007; April 1, 2008; December 1, 2008
+
****Describe how the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field will be changed if the proposed aims are achieved.
 
+
***(b) '''Innovation'''
 
+
****Explain how the application challenges and seeks to shift current research or clinical practice paradigms.
Expiration/Closing Date: January 18, 2008
+
****Describe any novel theoretical concepts, approaches or methodologies, instrumentation or interventions to be developed or used, and any advantage over existing methodologies, instrumentation, or interventions.
 
+
****Explain any refinements, improvements, or new applications of theoretical concepts, approaches or methodologies, instrumentation, or interventions.
'''Acknowledgement:''' NA-MIC would like to acknowledge that the format of this page was updated using that of the NCBC Simbios collaborations page.
+
***(c) '''Approach'''
 +
****Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project. Unless addressed separately in Item 15 (Resource Sharing Plan), include how the data will be collected, analyzed, and interpreted as well as any resource sharing plans as appropriate.
 +
****Discuss potential problems, alternative strategies, and benchmarks for success anticipated to achieve the aims.
 +
****If the project is in the early stages of development, describeany strategy to establish feasibility, and address the management of any high risk aspects of the proposed work.
 +
****Point any procedures, situations, or materials that may behazardous to personnel and precautions to be exercised. A full discussion on the use of Select Agents should appear in Item 11, below.
 +
****'''Preliminary Studies''' for New Applications: For new applications, include information on Preliminary Studies as part of the Approach section.
 +
****'''Progress Report for Renewal and Revision Applications:'''For renewal/revision applications, provide a Progress Report as part of the Approach section. Provide the beginning and ending dates for the period covered since the last competitive review. Summarize the specific aims of the previous project period and the importance of the findings, and emphasize the progress made toward their achievement.

Latest revision as of 10:32, 25 April 2012

Home < Collaborator:Resources
Back to NA-MIC Collaborations
  • This page contains information for prospective external collaborators. NIH has established funding sources for collaborating with the NCBC's.
  • Click here for a description of the process for collaborating with NA-MIC. This should be read first.

Please contact us if you are interested in a collaborative project with NA-MIC.

  • In addition to contacting the center, you are encouraged to contact the NIH Program Officer Vinay Pai, Ph.D. (NIBIB) or the Lead Science Officer Michael Ackermann, Ph.D. (NLM) for NA-MIC.

Please note key dates: standard NIH submission dates for R01s apply to this grant.

  • Notes 2010-03:
    • New forms
    • New structure: (page 108 of the pdf version)
      • 1 page specific aims
      • 12 pages for Research Strategy
      • (a) Significance:
        • Explain the importance of the problem or critical barrier to progress in the field that the proposed project addresses.
        • Explain how the proposed project will improve scientific knowledge, technical capability, and/or clinical practice in one or more broad fields.
        • Describe how the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field will be changed if the proposed aims are achieved.
      • (b) Innovation
        • Explain how the application challenges and seeks to shift current research or clinical practice paradigms.
        • Describe any novel theoretical concepts, approaches or methodologies, instrumentation or interventions to be developed or used, and any advantage over existing methodologies, instrumentation, or interventions.
        • Explain any refinements, improvements, or new applications of theoretical concepts, approaches or methodologies, instrumentation, or interventions.
      • (c) Approach
        • Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project. Unless addressed separately in Item 15 (Resource Sharing Plan), include how the data will be collected, analyzed, and interpreted as well as any resource sharing plans as appropriate.
        • Discuss potential problems, alternative strategies, and benchmarks for success anticipated to achieve the aims.
        • If the project is in the early stages of development, describeany strategy to establish feasibility, and address the management of any high risk aspects of the proposed work.
        • Point any procedures, situations, or materials that may behazardous to personnel and precautions to be exercised. A full discussion on the use of Select Agents should appear in Item 11, below.
        • Preliminary Studies for New Applications: For new applications, include information on Preliminary Studies as part of the Approach section.
        • Progress Report for Renewal and Revision Applications:For renewal/revision applications, provide a Progress Report as part of the Approach section. Provide the beginning and ending dates for the period covered since the last competitive review. Summarize the specific aims of the previous project period and the importance of the findings, and emphasize the progress made toward their achievement.